Check-MDR CT103XL

The most comprehensive CE-IVD assay for molecular beta-lactamase identification

Includes new carbapenemase and ESBL targets, including emerging types and those typically found in non-fermenters. Stay up-to-date, stay in control.

Product page

Multiplex real-time PCR ASSAYS

Accurate results in 2 hours directly from rectal swabs or cultures

Check-Points offers a range of rapid molecular assays

Our products support you in identifying and controlling the spread of carbapenemases, ESBLs and AmpCs & rapid molecular serotyping of Salmonella.

Antibiotic Resistance

Multidrug resistance (MDR) in Gram-negative bacteria is increasing sharply worldwide. This is causing once effective antibiotics to fail in treating infections ranging from common urinary tract infections to life-threatening bloodstream infections. Of major concern are bacteria that produce carbapenemases, ESBLs and AmpCs.

Quickly identify carriers

Patients who are colonized with resistant bacteria can silently transmit these to other patients who may in turn develop virtually incurable infections. Rapid testing helps healthcare facilities to learn of carriers early and to take measures to limit spread of resistant bacteria and thereby prevent outbreaks.
Learn more about our kits for active screening

Gain insight into epidemiology

Monitoring the molecular epidemiology of antibiotic resistance on a local or regional level can aid healthcare facilities, reference centers and research organizations in uncovering trends and emerging resistance threats. This requires an extended search for specific resistance genes that goes beyond the most prevalent types.
Learn more about our kits for epidemiology



22-25 April 2017, Reed Messe Vienna, Austria - Booth #132

More info


Check-Points is a privately owned diagnostics company founded in 2002 based in Wageningen, The Netherlands.

We focus on the development and commercialization of a new generation of molecular diagnostic solutions for specific routine applications in clinics, institutes and companies.